Table 3.
Characteristics of PBMC at T0 and T1.
| T0 | T1 | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall (n = 47) | PD (n = 17) | DC (n = 30) | p | Overall (n = 30) | PD (n = 5) | DC (n = 25) | p | |
|
Total Monocytes
CD14+, cells/μL |
427.6 (280.7; 620.3) |
354.6 (247.1; 585.5) |
436.2 (291.6; 716.0) |
0.501 | 331.5 (179.2; 536.2) |
392.2 (211.2; 573.8) |
325.8 (176.8; 567.6) * |
0.629 |
| CD14++ CD16−, cells/μL | 308.8 (168.9; 510.0) |
299.9 (113.3; 438.0) |
314.0 (168.9; 629.4) |
0.453 | 268.4 (144.4; 396.6) |
326.3 (170.7; 483.0) |
253.5 (141.1; 407.9) * |
0.581 |
| CD14+ CD16+, cells/μL | 7.0 (2.9; 22.4) |
6.4 (3.9;16.9) |
7.8 (1.9;25.3) |
0.959 | 5.5 (3.1;15.3) |
11.5 (3.1;16.2) |
5.2 (3.1;15.8) |
0.783 |
| CD14+ CD16++, cells/μL | 20.8 (14.6; 53.2) |
18.9 (16.0; 67.3) |
23.4 (13.9; 53.2) |
1.000 | 25.9 (19.5; 43.8) |
27.5 (10.7; 31.0) |
24.4 (19.5; 45.8) |
0.446 |
|
T lymphocytes
CD3+ CD56−, cells/μL |
822.4 (526.8; 1194.4) |
773.4 (455.7; 1147.8) |
911.6 (587.3; 1345.1) |
0.437 | 741.6 (509.6; 833.8) |
370.4 (234.3; 926.1) |
744.6 (636.0; 841.8) |
0.265 |
| CD4+, cells/μL | 284.8 (151; 551) |
215.6 (138.1; 612.9) |
320.6 (156.9; 543.7) |
0.445 | 264.8 (160.4; 307.8) |
167.6 (61.0; 289.1) |
265.3 (177.3; 312.3) |
0.275 |
| CD8+, cells/μL | 234.6 (105.2; 316.9) |
153.5 (96.4; 298.3) |
273.9 (132.9; 334.5) |
0.133 | 179.4 (91.6; 288.7) |
125.5 (54.5; 251.5) |
184.0 (98.6; 323.9) |
0.406 |
|
NK cells
CD3−CD56+, cells/μL |
63.6 (17.5; 151.7) |
27.8 (4.6; 57.6) |
127.0 (58; 210) |
<0.001 | 108.6 (53.6; 205.9) |
30.4 (15.3; 53.8) |
138.1 (94.5; 223.6) * |
< 0.001 |
| CD56dim, cells/μL | 45.5 (13; 129) |
16.8 (2.1; 49.0) |
85.9 (20.1; 146.7) |
0.003 | 89.2 (29.4; 129.0) |
29.0 (9.0; 41.1) * |
100.3 (64.2;145.2) |
0.009 |
| CD56bright, cells/μL | 12.0 (3.6; 31.2) |
6.7 (1.5; 17.6) |
18.1 (4.2; 49.0) |
0.047 | 17.9 (10.5; 69.8) * |
12.0 (10.0; 48.5) |
27.4 (10.4; 85.7) * |
0.357 |
| Ratio CD56bright/CD56dim | 0.20 (0.09; 1.13) |
0.49 (0.11; 1.27) |
0.16 (0.06; 0.77) |
0.239 | 0.24 (0.07;0.89) |
0.99 (0.78;1.12) |
0.17 (0.06; 0.77) |
0.462 |
|
B lymphocytes
CD19+, cells/μL |
92.6 (39.5;135.4) |
106.0 (44.4;203.6) |
61.6 (39.0;125.8) |
0.468 | 69.2 (40.9;93.4) |
41.4 (7.0;65.5) |
78.9 (42.1;96.4) |
0.044 |
At each time point, data are reported for the overall population and for subgroups based on best response: progression disease (PD) and disease control (DC). Data are expressed as median (IQR). Comparisons between the two groups were performed at each time point using Mann–Whitney U test. Wilcoxon test was used for longitudinal evaluation (T1 vs. T0): * indicates p < 0.05 for longitudinal evaluation.